DOVA - Dova Pharmaceuticals Looks To Expand Market Opportunity With Doptelet Targeting Another Indication
Dova Pharmaceuticals (DOVA) is a good biotech to look into because of its ability to use Doptelet to target patients with thrombocytopenia due to many different causes. Specifically, this biotech has been successful in developing a treatment for thrombocytopenia due to chronic liver disease ((CLD)). I think there is more upside for this biotech, especially with the focus to target the many other indications associated with thrombocytopenia.
Earnings For Doptelet
Doptelet has already been approved by the FDA to treat patients with thrombocytopenia due to CLD. The drug launched back in June of